

Christopher L King

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9035662/christopher-l-king-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69
papers

2,346
citations

27
h-index

48
g-index

74
ext. papers

2,770
ext. citations

8.5
avg, IF

4.53
L-index

#	Paper	IF	Citations
69	Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial.. <i>PLoS Neglected Tropical Diseases</i> , 2022 , 16, e0010096	4.8	1
68	Characterization of a novel microfilarial antigen for diagnosis of <i>Wuchereria bancrofti</i> infections. <i>PLoS Neglected Tropical Diseases</i> , 2022 , 16, e0010407	4.8	0
67	Community control strategies for scabies: A cluster randomised noninferiority trial. <i>PLoS Medicine</i> , 2021 , 18, e1003849	11.6	1
66	Significant Reduction in Vaccine-Induced Antibody Levels and Neutralization Activity Among Healthcare Workers and Nursing Home Residents 6 Months Following Coronavirus Disease 2019 BNT162b2 mRNA Vaccination.. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	7
65	Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?. <i>Aging Clinical and Experimental Research</i> , 2021 , 33, 3151-3160	4.8	3
64	Naturally acquired blocking human monoclonal antibodies to Plasmodium vivax reticulocyte binding protein 2b. <i>Nature Communications</i> , 2021 , 12, 1538	17.4	1
63	Individual Efficacy and Community Impact of Ivermectin, Diethylcarbamazine, and Albendazole Mass Drug Administration for Lymphatic Filariasis Control in Fiji: A Cluster Randomized Trial. <i>Clinical Infectious Diseases</i> , 2021 , 73, 994-1002	11.6	2
62	A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. <i>PLoS Neglected Tropical Diseases</i> , 2021 , 15, e0009002	4.8	5
61	Reduced BNT162b2 mRNA vaccine response in SARS-CoV-2-naive nursing home residents 2021 ,		10
60	Reduced BNT162b2 Messenger RNA Vaccine Response in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Naive Nursing Home Residents. <i>Clinical Infectious Diseases</i> , 2021 , 73, 2112-2115	11.6	29
59	Population Pharmacokinetics of Diethylcarbamazine in Patients with Lymphatic Filariasis and Healthy Individuals. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0031721	5.9	
58	Single-Dose Triple-Drug Therapy for - 5-Year Follow-up. <i>New England Journal of Medicine</i> , 2020 , 382, 1956-1957	59.2	11
57	The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial. <i>PLoS Neglected Tropical Diseases</i> , 2020 , 14, e0008106	4.8	11
56	Amplification of Duffy binding protein-encoding gene allows Plasmodium vivax to evade host anti-DBP humoral immunity. <i>Nature Communications</i> , 2020 , 11, 953	17.4	6
55	Is ivermectin safe in pregnancy?. <i>The Lancet Global Health</i> , 2020 , 8, e12-e13	13.6	5
54	Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Côte d'Ivoire: An Open-label Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2020 , 71, e68-e75	11.6	16
53	Pharmacokinetic and safety study of co-administration of albendazole, diethylcarbamazine, ivermectin and azithromycin for the integrated treatment of Neglected Tropical Diseases. <i>Clinical Infectious Diseases</i> , 2020 ,	11.6	2

52	Comparison of Repeated Doses of Ivermectin Versus Ivermectin Plus Albendazole for the Treatment of Onchocerciasis: A Randomized, Open-label, Clinical Trial. <i>Clinical Infectious Diseases</i> , 2020 , 71, 933-943	11.6	9
51	The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial 2020 , 14, e0008106		
50	The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial 2020 , 14, e0008106		
49	The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial 2020 , 14, e0008106		
48	The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial 2020 , 14, e0008106		
47	Systems analysis-based assessment of post-treatment adverse events in lymphatic filariasis. <i>PLoS Neglected Tropical Diseases</i> , 2019 , 13, e0007697	4.8	7
46	HIV, Cytomegalovirus, and Malaria Infections during Pregnancy Lead to Inflammation and Shifts in Memory B Cell Subsets in Kenyan Neonates. <i>Journal of Immunology</i> , 2019 , 202, 1465-1478	5.3	7
45	The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study. <i>PLoS Medicine</i> , 2019 , 16, e1002839	11.6	35
44	Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without <i>Wuchereria bancrofti</i> infection in Côte d'Ivoire. <i>PLoS Neglected Tropical Diseases</i> , 2019 , 13, e0007325	4.8	19
43	Identification and Characterization of Functional Human Monoclonal Antibodies to Duffy-Binding Protein. <i>Journal of Immunology</i> , 2019 , 202, 2648-2660	5.3	13
42	Dosing pole recommendations for lymphatic filariasis elimination: A height-weight quantile regression modeling approach. <i>PLoS Neglected Tropical Diseases</i> , 2019 , 13, e0007541	4.8	8
41	Hypergammaglobulinemia and Impaired Transplacental Transfer of Respiratory Syncytial Virus Antibody in Papua New Guinea. <i>Pediatric Infectious Disease Journal</i> , 2019 , 38, e199-e202	3.4	4
40	Changes in Cytokine, Filarial Antigen, and DNA Levels Associated With Adverse Events Following Treatment of Lymphatic Filariasis. <i>Journal of Infectious Diseases</i> , 2018 , 217, 280-287	7	7
39	Combining different diagnostic studies of lymphatic filariasis for risk mapping in Papua New Guinea: a predictive model from microfilaraemia and antigenaemia prevalence surveys. <i>Tropical Medicine and Health</i> , 2018 , 46, 41	3.4	2
38	A Trial of a Triple-Drug Treatment for Lymphatic Filariasis. <i>New England Journal of Medicine</i> , 2018 , 379, 1801-1810	59.2	86
37	Antibodies as epidemiological markers of genetically modified crop exposure: detection of Cry1Ab-specific IgG. <i>Food and Agricultural Immunology</i> , 2017 , 28, 779-788	2.9	4
36	An engineered vaccine of the <i>Plasmodium vivax</i> Duffy binding protein enhances induction of broadly neutralizing antibodies. <i>Scientific Reports</i> , 2017 , 7, 13779	4.9	16
35	Associations between an IgG3 polymorphism in the binding domain for FcRn, transplacental transfer of malaria-specific IgG3, and protection against <i>Plasmodium falciparum</i> malaria during infancy: A birth cohort study in Benin. <i>PLoS Medicine</i> , 2017 , 14, e1002403	11.6	23

34	Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa. <i>PLoS Neglected Tropical Diseases</i> , 2017 , 11, e0005163	4.8	42
33	<i>P. falciparum</i> infection and maternofetal antibody transfer in malaria-endemic settings of varying transmission. <i>PLoS ONE</i> , 2017 , 12, e0186577	3.7	14
32	A preliminary assessment of and gene polymorphisms in Papua New Guinea - what does it mean for HIV/AIDS?. <i>Papua and New Guinea Medical Journal</i> , 2017 , 60, 51-59		1
31	Identification of highly-protective combinations of recombinant proteins for vaccine development. <i>ELife</i> , 2017 , 6,	8.9	35
30	Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis. <i>Clinical Infectious Diseases</i> , 2016 , 62, 334-341	11.6	125
29	Population genomics of the filarial nematode parasite <i>Wuchereria bancrofti</i> from mosquitoes. <i>Molecular Ecology</i> , 2016 , 25, 1465-77	5.7	27
28	Naturally Acquired Binding-Inhibitory Antibodies to <i>Plasmodium vivax</i> Duffy Binding Protein and Clinical Immunity to Malaria in Rural Amazonians. <i>Journal of Infectious Diseases</i> , 2016 , 214, 1539-1546	7	27
27	Retraction for Siddiqui et al., Fine specificity of <i>Plasmodium vivax</i> Duffy binding protein binding engagement of the Duffy antigen on human erythrocytes. <i>Infection and Immunity</i> , 2015 , 83, 2593	3.7	
26	Biosignatures of Exposure/Transmission and Immunity. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015 , 93, 16-27	3.2	27
25	Risk factors for malaria and adverse birth outcomes in a prospective cohort of pregnant women resident in a high malaria transmission area of Papua New Guinea. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2015 , 109, 313-24	2	32
24	Liquid chromatography-mass spectrometry analysis of diethylcarbamazine in human plasma for clinical pharmacokinetic studies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014 , 98, 307-10	3.5	6
23	Natural acquisition of immunity to <i>Plasmodium vivax</i> : epidemiological observations and potential targets. <i>Advances in Parasitology</i> , 2013 , 81, 77-131	3.2	65
22	Finding the sweet spots of inhibition: understanding the targets of a functional antibody against <i>Plasmodium vivax</i> Duffy binding protein. <i>International Journal for Parasitology</i> , 2012 , 42, 1055-62	4.3	10
21	Fine specificity of <i>Plasmodium vivax</i> Duffy binding protein binding engagement of the Duffy antigen on human erythrocytes. <i>Infection and Immunity</i> , 2012 , 80, 2920-8	3.7	13
20	Fy(a)/Fy(b) antigen polymorphism in human erythrocyte Duffy antigen affects susceptibility to <i>Plasmodium vivax</i> malaria. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 20113-8	11.5	82
19	<i>Plasmodium vivax</i> clinical malaria is commonly observed in Duffy-negative Malagasy people. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 5967-71	11.5	267
18	Antibody-dependent transplacental transfer of malaria blood-stage antigen using a human ex vivo placental perfusion model. <i>PLoS ONE</i> , 2009 , 4, e7986	3.7	43
17	Can prenatal malaria exposure produce an immune tolerant phenotype? A prospective birth cohort study in Kenya. <i>PLoS Medicine</i> , 2009 , 6, e1000116	11.6	116

16	Do antenatal parasite infections devalue childhood vaccination?. <i>PLoS Neglected Tropical Diseases</i> , 2009 , 3, e442	4.8	101
15	Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children. <i>Infection and Immunity</i> , 2009 , 77, 4009-17	3.7	68
14	Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 8363-8	11.5	126
13	The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea. <i>PLoS Neglected Tropical Diseases</i> , 2008 , 2, e344	4.8	63
12	Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. <i>PLoS Medicine</i> , 2007 , 4, e337	11.6	137
11	Prenatal T cell immunity to Wuchereria bancrofti and its effect on filarial immunity and infection susceptibility during childhood. <i>Journal of Infectious Diseases</i> , 2006 , 193, 1005-13	7	67
10	Prenatal malaria immune experience affects acquisition of Plasmodium falciparum merozoite surface protein-1 invasion inhibitory antibodies during infancy. <i>Journal of Immunology</i> , 2006 , 177, 7139-45	5.3	38
9	Distinct Th1- and Th2-Type prenatal cytokine responses to Plasmodium falciparum erythrocyte invasion ligands. <i>Infection and Immunity</i> , 2005 , 73, 3462-70	3.7	78
8	Epitope-specific humoral immunity to Plasmodium vivax Duffy binding protein. <i>Infection and Immunity</i> , 2003 , 71, 2508-15	3.7	44
7	Acquired immune responses to Plasmodium falciparum merozoite surface protein-1 in the human fetus. <i>Journal of Immunology</i> , 2002 , 168, 356-64	5.3	91
6	Cloning, sequencing, and homology analysis of nonhuman primate Fas/Fas-ligand and co-stimulatory molecules. <i>Immunogenetics</i> , 2001 , 53, 315-28	3.2	30
5	An overview of animal models in experimental schistosomiasis and refinements in the use of non-human primates. <i>Laboratory Animals</i> , 2001 , 35, 205-12	2.6	27
4	Increased levels of soluble interleukin-4 receptor in the sera of patients with visceral leishmaniasis. <i>Journal of Infectious Diseases</i> , 1999 , 179, 743-6	7	17
3	CD28-deficient mice generate an impaired Th2 response to Schistosoma mansoni infection. <i>European Journal of Immunology</i> , 1996 , 26, 2448-55	6.1	65
2	CD28 activation promotes Th2 subset differentiation by human CD4+ cells. <i>European Journal of Immunology</i> , 1995 , 25, 587-95	6.1	107
1	Duffy Antigen Expression in Erythroid Bone Marrow Precursor Cells of Genotypically Duffy Negative Individuals		5